Anakinra for Lung Transplant Recipients

This trial aims to determine if the drug Anakinra can prevent primary graft dysfunction in lung transplant recipients. Primary graft dysfunction causes low oxygen levels and fluid or inflammation in the lungs post-transplant. In the treatment group, Anakinra will be added to the solution that maintains donor lung health before the transplant. The trial seeks participants planning a lung transplant using a technique called ex vivo lung perfusion (EVLP). As an Early Phase 1 trial, this research focuses on understanding how Anakinra works in people, offering participants an opportunity to contribute to groundbreaking medical knowledge.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that Anakinra, the treatment being tested in this trial, is usually well-tolerated in other situations. The FDA has already approved Anakinra for treating conditions like rheumatoid arthritis, indicating its safety in those cases. However, since this trial is in its early stages, researchers are still studying Anakinra's safety specifically for lung transplants. Detailed information about side effects in this specific context is not yet available, but its testing suggests that early research supports its potential safety and effectiveness.¹²³⁴⁵

Most treatments for lung transplant patients focus on preventing organ rejection and managing infections with immunosuppressants and antibiotics. But Anakinra works differently, targeting inflammation by blocking a protein called interleukin-1 (IL-1), which plays a key role in inflammatory responses. Researchers are excited about Anakinra because it can be administered directly into the lung perfusion solution during ex vivo lung perfusion (EVLP), potentially reducing inflammation right before the transplant. This novel approach could lead to better transplant outcomes and improved lung function post-surgery.

Research suggests that Anakinra might help reduce inflammation in lung transplant recipients. Anakinra blocks a protein called IL-1, which causes inflammation. In this trial, one group will receive Anakinra during ex vivo lung perfusion (EVLP) to assess its impact on donor lungs. Studies have shown that controlling IL-1 can improve the condition of donor lungs during EVLP, a process used to prepare lungs for transplant. This method has been linked to better outcomes in lung transplants. Although specific data on using Anakinra for this purpose is limited, its potential to reduce inflammation is promising.²⁵⁶⁷⁸